300 related articles for article (PubMed ID: 19925499)
1. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Giannini EG; Basso M; Savarino V; Picciotto A
Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
3. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
4. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
5. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
[TBL] [Abstract][Full Text] [Related]
6. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
Bate JP; Colman AJ; Frost PJ; Shaw DR; Harley HA
J Gastroenterol Hepatol; 2010 Jul; 25(7):1276-80. PubMed ID: 20594255
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
8. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
[TBL] [Abstract][Full Text] [Related]
9. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
Formann E; Steindl-Munda P; Hofer H; Jessner W; Bergholz U; Gurguta C; Ferenci P
Aliment Pharmacol Ther; 2006 Feb; 23(4):507-11. PubMed ID: 16441471
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
12. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
[TBL] [Abstract][Full Text] [Related]
13. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
14. Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV).
Younossi ZM; Limongi D; Stepanova M; Pierobon M; Afendy A; Mehta R; Baranova A; Liotta L; Petricoin E
J Proteome Res; 2011 Feb; 10(2):774-9. PubMed ID: 21204552
[TBL] [Abstract][Full Text] [Related]
15. [Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Lee JE; Yoon NR; Kim JD; Song MJ; Kwon JH; Bae SH; Choi JY; Jeong SW; Yoon SK
Korean J Gastroenterol; 2011 Mar; 57(3):173-9. PubMed ID: 21519165
[TBL] [Abstract][Full Text] [Related]
16. Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.
Choi SB; Lee YJ; Lee JI; Song YJ; Choi BJ; Kim JH; Jung EU; Park SJ; Lee SH; Kim JH; Choi JS; Jee SR; Seol SY
Korean J Hepatol; 2011 Sep; 17(3):183-8. PubMed ID: 22102384
[TBL] [Abstract][Full Text] [Related]
17. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
Wang X; Gao F; Yuan G; Shi K; Huang Y; Chen Y; Qiu R; Sun L; Liu J; Hu C; Zhou Y
J Viral Hepat; 2016 Dec; 23(12):971-976. PubMed ID: 27453300
[TBL] [Abstract][Full Text] [Related]
18. Decreased anti-hepatitis C virus titer and associated factors in chronic hepatitis C patients after sustained virological response: a prospective study.
Kee KM; Wang JH; Hung CH; Chen CH; Lee CM; Chang KC; Tseng PL; Yen YH; Lin CY; Lu SN
J Gastroenterol Hepatol; 2012 Jun; 27(6):1106-11. PubMed ID: 22004331
[TBL] [Abstract][Full Text] [Related]
19. Discrepancy in virological and biochemistry response of patients with chronic hepatitis HCV positive on treatment with PEG-IFN plus ribavirin.
Marino N; Blanc PL; Blè C; Pierotti P; Mazzotta F
J Biol Regul Homeost Agents; 2003; 17(2):205-6. PubMed ID: 14518725
[TBL] [Abstract][Full Text] [Related]
20. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.
Colson P; Bregigeon S; Tourres C; Solas C; Poizot-Martin I; Tamalet C
J Clin Virol; 2013 Sep; 58(1):309-14. PubMed ID: 23810614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
